<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010397731</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010397731</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Hennig</surname><given-names>Stefanie</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Nyberg</surname><given-names>Joakim</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Fanta</surname><given-names>Samuel</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Backman</surname><given-names>Janne T.</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Hoppu</surname><given-names>Kalle</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Hooker</surname><given-names>Andrew C.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Karlsson</surname><given-names>Mats O.</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010397731">Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (Dr Hennig, Mr Nyberg, Dr Fanta, Dr Hooker, Dr Karlsson)</aff>
<aff id="aff2-0091270010397731">Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland (Dr Fanta, Dr Backman, Dr Hoppu)</aff>
<aff id="aff3-0091270010397731">Hospital for Children and Adolescents, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland (Dr Hoppu)</aff>
<author-notes>
<corresp id="corresp1-0091270010397731">Stefanie Hennig, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE 751 24 Uppsala, Sweden; e-mail: <email>stefanie.hennig@farmbio.uu.se</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>347</fpage>
<lpage>360</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>10</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>A time and sampling intensive pretransplant test dose design was to be reduced, but at the same time optimized so that there was no loss in the precision of predicting the individual pharmacokinetic (PK) estimates of posttransplant dosing. The following variables were optimized simultaneously: sampling times, ciclosporin dose, time of second dose, infusion duration, and administration order, using a published ciclosporin population PK model as prior information. The original design was reduced from 22 samples to 6 samples/patient and both doses (intravenous oral) were administered within 8 hours. Compared with the prior information given by the published ciclosporin population PK model, the expected standard deviations (SDs) of the individual parameters for clearance and bioavailability could be reduced by, on average, 40% under the optimized sparse designs. The gain of performing the original rich design compared with the optimal reduced design, considering the standard errors of the parameter estimates, was found to be minimal. This application demonstrates, in a practical clinical scenario, how optimal design techniques may be used to improve diagnostic procedures given available software and methods.</p>
</abstract>
<kwd-group>
<kwd>Ciclosporin</kwd>
<kwd>therapeutic drug monitoring</kwd>
<kwd>optimal design</kwd>
<kwd>diagnostics</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>From 1988 to 2005, all pediatric renal transplant patients at the Hospital for Children and Adolescents of the University of Helsinki, Finland, underwent an intensive pretransplant pharmacokinetic (PK) dose finding study of the immunosuppressive agent ciclosporin to establish a good estimate for an individualized posttransplant dose. A total of 162 patients received an intravenous (IV) dose of ciclosporin and 89 patients received an oral (PO) dose with 77 of these receiving both formulations of ciclosporin (<xref ref-type="fig" rid="fig1-0091270010397731">Figure 1</xref>). These patients represent the entire pediatric population that underwent renal transplantation and received ciclosporin in Finland during this time period. At the time, these individual studies were used to first predict the IV dose, and then the first PO posttransplant dose using individual modeling or noncompartmental PKs.<sup><xref ref-type="bibr" rid="bibr1-0091270010397731">1</xref></sup></p>
<fig id="fig1-0091270010397731" position="float">
<label>Figure 1.</label>
<caption>
<p>The figure shows a total of 77 ciclosporin concentration-time profiles using an IVPO (intravenous dose first, oral dose second) setup given the discrete individual parameter distributions. Both doses are within an 8-hour time interval with the second dose being administered at 4 hours.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397731-fig1.tif"/>
</fig>
<p>The sampling procedure for this dose finding study, described in detail by Fanta et al,<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> included 12 samples taken within 0 to 28 hours after the IV dose, and 10 samples taken within 0 to 24 hours after the PO dose. Clinically, it would be desirable to simplify this intensive pretransplant PK test design, because it is not only time consuming and expensive but also demanding on the patients. The following simplifications were considered ideal for implementation in clinical routine: both doses given during the same day, a maximum of 3 samples per dose per patient, and a total observation period of 8 hours. This would ease the patient sample burden and enable them to carry out the entire procedure during a single visit to the clinic, without an overnight stay as an inpatient. However, restrictions on a maximum oral dose and a maximum infusion rate of 0.75 mg/kg/h given by the clinical team had to be included as well. With the above simplifications, these sparse pretransplant designs will clearly result in less information than the rich design. It would therefore be useful to optimize these sparse pretransplant test dose designs to maximize the information used to derive the individual PK estimates for prediction of posttransplant dosing.</p>
<p>One way to improve the information content of sparse individual PK data is to borrow information from a population of similar individuals. In 2007, Fanta et al presented a population model on this data,<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> which can be used to calculate individual parameter estimates using Bayesian methodology. Empirical Bayes estimates (EBEs) represent estimates that are informed by both population parameters and the individual’s observations. If the individual does not provide sufficient information to estimate their PK parameters separately, the EBEs will be estimated to be close to the population parameter values, and this individual will be a “typical patient” regarding the parameter values (which can be referred to as η-shrinkage<sup><xref ref-type="bibr" rid="bibr3-0091270010397731">3</xref></sup>). Dose predictions using EBEs can thus be used even if an individual has sparse data, albeit less precisely toward that individual’s true values.</p>
<p>A second way to improve the information content of sparse individual PK data is to change the design parameters of the study to improve the information content. Other publications have previously tried to improve monitoring designs for immunosuppressive agents; however, all of these studies have only adjusted the sampling times and/or the number of samples.<sup><xref ref-type="bibr" rid="bibr4-0091270010397731">4</xref>-<xref ref-type="bibr" rid="bibr6-0091270010397731">6</xref></sup> In addition to the sampling times after the IV (xt<sub>IV</sub>) and the PO dose (xt<sub>PO</sub>) and the number of sampling times (n<sub>IV</sub>, n<sub>PO</sub>), other design parameters could also be considered for optimization (and in this example must be considered to achieve the clinically desired simplifications) including the dosing interval (t<sub>2nd dose</sub>), the amount of IV (Dose<sub>IV</sub>) and PO ciclosporin given (Dose<sub>PO</sub>), the duration of infusion for the IV dose (D<sub>inf</sub>), and the order of the given doses (Dose<sub>order</sub>).</p>
<p>In this study we use the optimal design approach to optimize the pretransplant dose finding procedure for ciclosporin for all of the above mentioned design parameters (xt<sub>IV</sub>, xt<sub>PO</sub>, n<sub>IV</sub>, n<sub>PO</sub>, t<sub>2nd dose</sub>, Dose<sub>IV</sub>, Dose<sub>PO</sub>, D<sub>inf</sub>, Dose<sub>order</sub>). This approach has been used previously to optimize population study design for clinical studies, eg, Hennig et al,<sup><xref ref-type="bibr" rid="bibr7-0091270010397731">7</xref>,<xref ref-type="bibr" rid="bibr8-0091270010397731">8</xref></sup> and as we do here, to minimize the uncertainty of the expected individual parameters,<sup><xref ref-type="bibr" rid="bibr9-0091270010397731">9</xref>,<xref ref-type="bibr" rid="bibr10-0091270010397731">10</xref></sup> where population parameters are used as prior information (it minimizes the uncertainty of the maximum a posteriori [MAP] estimate of an individual). In the case presented here, the population parameters come from the population model presented by Fanta et al.<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup></p>
<p>The goal of this study was to find fixed designs (the same for each individual) that could, on average, minimize the uncertainty of individual parameters used for dose prediction. For this reason, a distribution of possible individual parameters was used in the optimization. This procedure is similar to E-family optimal design,<sup><xref ref-type="bibr" rid="bibr11-0091270010397731">11</xref></sup> which is typically used in population optimal design to represent uncertainty in the population parameters. However, instead of incorporating uncertainty in the population parameters, uncertainty was included on the individual parameter level as discrete distributions. The discrete distributions of possible individual parameters were derived from the 77 individual parameter value combinations (EBEs) provided by the individuals in the population study mentioned above, to account correctly for covariates and correlations.</p>
<p>The designs presented here also investigate S-family design criterions<sup><xref ref-type="bibr" rid="bibr12-0091270010397731">12</xref></sup> (specifically, D<sub>s</sub>-optimality), which account for the relative importance of the individual parameters in our model. These designs were used to give more importance to, for example, individual clearance (CL<sub>i</sub>) and bioavailability (F<sub>i</sub>), because these parameters are most important in determining average steady state drug concentration (C<sub>ss,ave,i</sub> = Dose rate (R<sub>0</sub>)*F<sub>i</sub>/CL<sub>i</sub>). The following 3 different scenarios of parameter subsets of interest in the model were evaluated: (1) CL<sub>i</sub> and F<sub>i</sub>, (labeled as “CL and F” in this work); (2) the MAP estimates of the 6 structural PK parameters (MAP 6); and (3) all 8 individual parameters, including the residual unexplained variability (RUV) for both the PO and IV models (MAP all), provided by the population model.</p>
<p>Here we present a typical clinical scenario—how to adjust a test dose design to improve the information that will be used to treat the individual patient in the future. With this example, several optimal design methodologies are combined (simultaneous optimization of several design aspects, individual parameter optimization, the D<sub>s</sub>-design criteria, and discrete parameter distributions for MAP optimization) and implemented using available optimal design software tools. Thus, the work presented here may help as a methodological guide to improve other clinical studies or diagnostic procedures used to guide treatment individualization.</p>
<sec id="section1-0091270010397731" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010397731">
<title>Population PK Model for Ciclosporin</title>
<p>The population PK model for ciclosporin described by Fanta et al<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> is a linear 3-compartment model with first-order absorption, including between subject variability (BSV) on all PK parameters as well as on the residual unexplained variability (RUV) terms. However, the BSV model for central and second peripheral volumes (V2, V4) and the corresponding intercompartmental clearance (Q4) share the same BSV (allowing for complete correlation), but with different magnitudes (using a scaling factor). Bioavailability (F) was included in the model using a logit function to restrict the value of F to be between 0 and 1. The RUV model was published as a combined additive (1.5 mcg/L) and proportional (0.298%) model for the IV formulation, and a proportional error of 0.45% for the PO formulation. For the design optimization an additive component of 1.5 mcg/L was also added to the PO RUV model. Total body weight, allometricaly scaled, was included in the model as the main covariate effect on all clearance and volume terms. This population PK study provided both model and population parameter values that could be used as prior information for future TDM, and a large data set including individual parameter estimates.</p>
</sec>
<sec id="section3-0091270010397731">
<title>Optimization</title>
<p>The model was implemented in the optimal design software PopED v.2.08,<sup><xref ref-type="bibr" rid="bibr13-0091270010397731">13</xref></sup> which is written in MATLAB (MATLAB vs 7.4.0.287). Optimizations were performed using either D or D<sub>s</sub>-optimality using the 3 scenarios described above (CL and F, MAP 6, and MAP all). Three samples per dose were allowed and a total sampling period of 8 hours was allowed for both doses (IV and PO combined). The following design variables were optimized simultaneously<sup><xref ref-type="bibr" rid="bibr14-0091270010397731">14</xref></sup>: xt<sub>IV</sub>, xt<sub>PO</sub>, Dose<sub>IV</sub>, Dose<sub>PO</sub>, D<sub>inf</sub>, and t<sub>2nd dose</sub>. The total ciclosporin dose (IV + PO) was restricted to 10 mg/kg, where the Dose<sub>PO</sub> = 10 mg/kg - Dose<sub>IV</sub> and the infusion rate was restricted to be maximally 0.75 mg/kg/h for the IV formulation (to avoid anaphylactoid reaction to the cremophor compound in the IV infusion formulation). The impact of the order of administration of the formulation, IV dose first (IVPO) versus PO dose first (POIV), on the informativeness of the design, was assessed for all 3 cases considered.</p>
<sec id="section4-0091270010397731">
<title>Optimization of FIM<sub>MAP</sub></title>
<p>In this work, the population model described above was assumed known and was included as prior information. The aim here was to optimize the pretransplantation design with respect to the uncertainty of the MAP estimated individual parameters and not the population parameters. Merlé and Mentré have previously optimized designs using the Bayesian criteria with the inclusion of priors.<sup><xref ref-type="bibr" rid="bibr9-0091270010397731">9</xref>,<xref ref-type="bibr" rid="bibr10-0091270010397731">10</xref></sup> Here, a similar method was applied but the inclusion of the priors was adopted from Jonsson et al,<sup><xref ref-type="bibr" rid="bibr15-0091270010397731">15</xref></sup> and sampling from the previous population’s EBEs was used to include information about the potential individual parameter values of new individuals.</p>
<p>The method used here entails transforming the individual parameter estimates to fixed effects in a population model with the population parameters used as prior information. Briefly, in a population model, we define the <italic>k</italic>th parameter estimate for the <italic>i</italic>th individual, as:</p>
<p><disp-formula id="disp-formula1-0091270010397731">
<label>(1)</label>
<mml:math display="block" id="math1-0091270010397731">
<mml:mrow>
<mml:msub>
<mml:mi>p</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>×</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>η</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010397731" xlink:href="10.1177_0091270010397731-eq1.tif"/>
</disp-formula></p>
<p>where the <italic>k</italic>th parameter’s deviation from the typical parameter value θ<sub><italic>k</italic></sub> in the population is denoted η<sub><italic>ik</italic></sub> and is often assumed to be normally distributed with a mean of 0 and a variance of <inline-formula id="inline-formula1-0091270010397731">
<mml:math display="inline" id="math2-0091270010397731">
<mml:mrow>
<mml:msubsup>
<mml:mi>ω</mml:mi>
<mml:mi>k</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>. In nonlinear mixed effect modeling the <italic>p<sub>ik</sub></italic>s are often log-normally transformed, as in <xref ref-type="disp-formula" rid="disp-formula1-0091270010397731">Equation 1</xref>, to avoid negative parameter values. η<sub><italic>ik</italic></sub> can be estimated using empirical Bayes estimation<sup><xref ref-type="bibr" rid="bibr16-0091270010397731">16</xref></sup> from the observed data of individual <italic>i</italic> and a population model with population parameter estimates. In an optimal design framework, to transform the individual parameter estimates to fixed effects (transforming the model to an individual model), we rewrite <xref ref-type="disp-formula" rid="disp-formula1-0091270010397731">Equation 1</xref> as:</p>
<p><disp-formula id="disp-formula2-0091270010397731">
<label>(2)</label>
<mml:math display="block" id="math3-0091270010397731">
<mml:mrow>
<mml:msub>
<mml:mi>p</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msup>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010397731" xlink:href="10.1177_0091270010397731-eq2.tif"/>
</disp-formula></p>
<p>In the current setting, we are interested in estimating θ<sup><italic>i,k</italic></sup> for each individual as well as possible (assuming that θ<sub><italic>k</italic></sub> are known and fixed). We add priors on these individual parameters based on the population variances of these parameters <inline-formula id="inline-formula2-0091270010397731">
<mml:math display="inline" id="math4-0091270010397731">
<mml:mrow>
<mml:msubsup>
<mml:mi>ω</mml:mi>
<mml:mi>k</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>.</p>
<p>To minimize parameter uncertainty, optimal design methods often utilize the Fisher information matrix (FIM), which according to the Cramér-Rao inequality is a lower bound to the inverse of the variance-covariance (var-cov) matrix of parameter estimates. That is, the study design that gives the largest FIM will provide the most precise parameter estimates. The size of the FIM is most commonly measured by its determinant (D-optimal design), a scalar measure of the matrix. For a specific set of individuals we have:</p>
<p><disp-formula id="disp-formula3-0091270010397731">
<label>(3)</label>
<mml:math display="block" id="math5-0091270010397731">
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>M</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>Θ</mml:mi>
<mml:mi>j</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msup>
<mml:mi>Ω</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010397731" xlink:href="10.1177_0091270010397731-eq3.tif"/>
</disp-formula></p>
<p>with <inline-formula id="inline-formula3-0091270010397731">
<mml:math display="block" id="math6-0091270010397731">
<mml:mrow>
<mml:mi>Ω</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mi>ω</mml:mi>
<mml:mn>1</mml:mn>
<mml:mn>2</mml:mn>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:msubsup>
<mml:mi>ω</mml:mi>
<mml:mi>s</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> providing the prior population information (diag() indicates a diagonal matrix), X are the design variables (sample times, doses, etc), Θ<sub><italic>j</italic></sub> is a list of individual parameter values, defined specifically for the model used in this work as:</p>
<p><disp-formula id="disp-formula4-0091270010397731">
<label>(4)</label>
<mml:math display="block" id="math7-0091270010397731">
<mml:mrow>
<mml:msub>
<mml:mi>Θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">[</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:msub>
<mml:mtext>L</mml:mtext>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>V</mml:mi>
<mml:mn>2</mml:mn>
<mml:mspace width="0.5em"/>
<mml:mi>Q</mml:mi>
<mml:mn>4</mml:mn>
<mml:mspace width="0.5em"/>
<mml:mi>V</mml:mi>
<mml:mn>4</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mtext>k</mml:mtext>
<mml:msub>
<mml:mtext>a</mml:mtext>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:msub>
<mml:mtext>F</mml:mtext>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mi>V</mml:mi>
<mml:msub>
<mml:mn>3</mml:mn>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mi>Q</mml:mi>
<mml:msub>
<mml:mn>3</mml:mn>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mtext>RUV</mml:mtext>
<mml:mspace width="0.5em"/>
<mml:mtext>I</mml:mtext>
<mml:msub>
<mml:mtext>V</mml:mtext>
<mml:mtext>i</mml:mtext>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mtext>RUV</mml:mtext>
<mml:mspace width="0.5em"/>
<mml:mtext>P</mml:mtext>
<mml:msub>
<mml:mtext>O</mml:mtext>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-0091270010397731" xlink:href="10.1177_0091270010397731-eq4.tif"/>
</disp-formula></p>
<p>To account for different possible individual parameter values, we sample from the previous population of individuals</p>
<p><disp-formula id="disp-formula5-0091270010397731">
<label>(5)</label>
<mml:math display="block" id="math8-0091270010397731">
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mn>1</mml:mn>
<mml:mrow>
<mml:mn>77</mml:mn>
</mml:mrow>
</mml:mfrac>
<mml:munderover>
<mml:mstyle displaystyle="true" mathsize="140%">
<mml:mo>∑</mml:mo>
</mml:mstyle>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mn>77</mml:mn>
</mml:mrow>
</mml:munderover>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>M</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>Θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo>+</mml:mo>
<mml:msup>
<mml:mi>Ω</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-0091270010397731" xlink:href="10.1177_0091270010397731-eq5.tif"/>
</disp-formula></p>
<p>and the D-optimal objective function to be maximized by changing design parameters is</p>
<p><disp-formula id="disp-formula6-0091270010397731">
<label>(6)</label>
<mml:math display="block" id="math9-0091270010397731">
<mml:mrow>
<mml:mi>O</mml:mi>
<mml:mi>F</mml:mi>
<mml:msub>
<mml:mi>V</mml:mi>
<mml:mi>D</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo>|</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>|</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0091270010397731" xlink:href="10.1177_0091270010397731-eq6.tif"/>
</disp-formula></p>
<p><xref ref-type="disp-formula" rid="disp-formula3-0091270010397731">Equation 3</xref> is similar to the previously proposed Bayesian information matrix (see Equation 23<sup><xref ref-type="bibr" rid="bibr10-0091270010397731">10</xref></sup>); however, here we use discrete sampling based on the EBEs obtained from the population model<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> compared with the sampling from discrete density distributions of parameter vectors with associated probabilities done by Merlé et al.<sup><xref ref-type="bibr" rid="bibr10-0091270010397731">10</xref></sup></p>
<p>Ω<sup>−1</sup> in <xref ref-type="disp-formula" rid="disp-formula3-0091270010397731">Equation 3</xref> represents the added prior var-cov matrix on these individual parameter values. In this work, Ω comes from the BSV terms (the <inline-formula id="inline-formula4-0091270010397731">
<mml:math display="inline" id="math10-0091270010397731">
<mml:mrow>
<mml:msubsup>
<mml:mi>ω</mml:mi>
<mml:mi>k</mml:mi>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>s) in<xref ref-type="disp-formula" rid="disp-formula1-0091270010397731">Equation 1</xref> and is defined as (with the same order of parameters as in <xref ref-type="disp-formula" rid="disp-formula4-0091270010397731">Equation 4</xref>):</p>
<p><disp-formula id="disp-formula7-0091270010397731">
<label>(7)</label>
<mml:math display="block" id="math11-0091270010397731">
<mml:mrow>
<mml:mi>Ω</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>29</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>6</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>2</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>18</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>76</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>04</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>1</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>85</mml:mn>
<mml:mo>,</mml:mo>
<mml:mspace width="0.5em"/>
<mml:mn>2</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>69</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mn>10</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-0091270010397731" xlink:href="10.1177_0091270010397731-eq7.tif"/>
</disp-formula></p>
<p>Additionally, covariate correlations (such as between WT and CL and V) are included in this function within each individual.</p>
<p>In this transformation, population parameters θ<sub><italic>k</italic></sub> of the model are fixed, which means that they are assumed to be known in the calculation of the FIM<sub>MAP</sub> and will not be estimated in future studies.</p>
</sec>
<sec id="section5-0091270010397731">
<title>Discrete Distributions Sampling and Covariate Relationships</title>
<p>In the previous pediatric population PK study, 77 patients had received both an IV and a PO test dose of ciclosporin. In <xref ref-type="fig" rid="fig1-0091270010397731">Figure 1</xref>, 77 individual PK ciclosporin profiles utilizing the individual parameters from the original study are visualized with a design example in which both formulations are administered within an 8-hour time frame, including an infusion time of 2 hours for a 1-mg/kg IV dose, and a 9-mg/kg PO dose administered at 4 hours post-IV dose. During design optimization, the individual parameters in the model θ<sub><italic>i,k</italic></sub> were assumed to have a discrete distribution corresponding to the 77 individual EBE parameters from the original study (<xref ref-type="disp-formula" rid="disp-formula5-0091270010397731">Equation 5</xref>).</p>
<p>Using this approach, the correlation between parameters is automatically included as well as the correlation between parameters and the covariate (weight). Future patients’ distribution should be reflected within this relatively large amount of individual parameter vectors; however, there might be a potential for bias toward previous patients in these calculated designs. However, the EBEs used from the previous experiment (the list of Θ<sub><italic>i</italic></sub>s) had, on average, a shrinkage of only 6%, because this analysis was based on very rich data. Therefore, the estimation method used in the population analysis (FOCEI) is expected to provide quite unbiased parameter estimates.<sup><xref ref-type="bibr" rid="bibr17-0091270010397731">17</xref></sup> Consequently, the η<sub><italic>ik</italic></sub> were not shrunk toward the population mean, but reflect the individual’s PK profile.<sup><xref ref-type="bibr" rid="bibr17-0091270010397731">17</xref></sup> Furthermore, the discrete distribution of the 8 EBEs had a relatively normally distributed shape with a mean close to 0.</p>
<p>Total body weight (WT) was included into the model as a covariate on clearance and volumes allometricaly<sup><xref ref-type="bibr" rid="bibr18-0091270010397731">18</xref></sup> as in the model presented by Fanta et al. The patients were dosed in the original study on an mg/kg basis and this was proposed for the future design as well. Therefore, the IV and PO doses were optimized as a function of WT. To do this, WT was also included as a discrete distributed vector of the weights obtained from the same 77 individuals as mentioned above.</p>
</sec>
</sec>
<sec id="section6-0091270010397731">
<title>D and D<sub>s</sub> Optimal Design</title>
<p>Designs were to be evaluated according to 3 different scenarios of parameter subsets of interest in the model. In the first case, referred to as clearance and bioavailability scenario (CL and F), the focus was to be able to estimate clearance and bioavailability scenario (CL and F) as precise as possible for TDM during chronic dosing (c<sub>average</sub> = R0IV dose first (IVPO) versus PO dose first (POIV),*F/CL). In the second case, labeled as “MAP 6”, the interest was to estimate all 6 individual fixed effect parameter as well as possible. For both of these cases all other parameters were labeled uninteresting.</p>
<p>To allow for optimization of subsets of parameters (CL and F, and MAP 6) the D<sub>s</sub> OFV was maximized with respect to design parameters in the optimal design calculations:</p>
<p><disp-formula id="disp-formula8-0091270010397731">
<label>(8)</label>
<mml:math display="block" id="math12-0091270010397731">
<mml:mrow>
<mml:mi>O</mml:mi>
<mml:mi>F</mml:mi>
<mml:msub>
<mml:mi>V</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>D</mml:mi>
<mml:mi>s</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mo>|</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>|</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>|</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
<mml:mo>_</mml:mo>
<mml:mi>u</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
<mml:mi>g</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>|</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0091270010397731" xlink:href="10.1177_0091270010397731-eq8.tif"/>
</disp-formula></p>
<p>Here, the FIM<sub>MAP</sub> is shown in <xref ref-type="disp-formula" rid="disp-formula5-0091270010397731">Equation 5</xref> and FIM<sub>MAP_uninteresting</sub> are the rows and columns of FIM<sub>MAP</sub> corresponding to the uninteresting parameters to be estimated in the experiment. For clarification, during optimization the smaller the FIM<sub>MAP_uninteresting</sub> was in relation to the FIM<sub>MAP</sub>, the larger OFV<sub>Ds</sub> will be, and therefore more emphasis will be put on the parameters of interest. Using D-optimality for subsets would have required the so-called uninteresting parameters to be to “fixed” and consequently deleted from the FIM and the OFV calculations.</p>
<p>However, for the third scenario, called “MAP all”, all 8 EBEs of the previous model were to be estimated (including the RUV); therefore, no subsets of parameters were of specific interest and therefore the OFV<sub>D</sub> (<xref ref-type="disp-formula" rid="disp-formula6-0091270010397731">Equation 6</xref>) was used.</p>
</sec>
<sec id="section7-0091270010397731">
<title>Further Design Reduction</title>
<p>Further reducing the number of samples per dose was investigated using the CL and F scenario with IVPO dosing. With this scenario, balanced sampling (3, 2, or 1 sample per dose) as well as unbalanced sampling (a total of 6, 5, 4, 3, or 2 samples) was investigated. For the latter case, the design was optimized for the number of samples per dose, to investigate the importance of the PO and IV dosing.</p>
<p>Finally, the potential to use just PO or IV dosing was investigated for the 3 cases described above. All design and optimization criterion were kept the same for this case; however, when the model was reduced to the PO model, only 7 individual parameters were optimized for (excluding the parameter for RUV of the IV model) and the optimized design variables were reduced to xt<sub>PO</sub> and Dose<sub>PO</sub>. When the model was reduced to the IV model, only 5 individual parameters were optimized for (excluding the parameters for ka, F, and RUV of the PO model) and the optimized design variables were reduced to xt<sub>IV</sub>, Dose<sub>IV</sub>, and D<sub>inf</sub>.</p>
</sec>
<sec id="section8-0091270010397731">
<title>Design Comparison</title>
<p>The different optimal designs were compared in 2 ways. First, the expected standard deviation (SD<sub>ind,k</sub>) for the <italic>k</italic>th parameter estimate for an individual was compared between designs, which was computed for designs as:</p>
<p><disp-formula id="disp-formula9-0091270010397731">
<label>(9)</label>
<mml:math display="block" id="math13-0091270010397731">
<mml:mrow>
<mml:mtext>S</mml:mtext>
<mml:msub>
<mml:mtext>D</mml:mtext>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:msubsup>
<mml:mrow>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">]</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-0091270010397731" xlink:href="10.1177_0091270010397731-eq9.tif"/>
</disp-formula></p>
<p>where <italic>k,k</italic> is the <italic>k</italic>th diagonal element of the inverse information matrix. The SDs are used for comparison instead of relative standard errors (RSE), because the means of the EBEs, used for the sampling, are normally distributed around zero. The mean of the EBEs are used in the calculation of the RSE as the denominator, which will result in a division by zero. However, the SDs could be translated to CV (%) by multiplying by 100 (except for F which is logit transformed in the model).</p>
<p>Second, the designs can be compared using the OFVs used in design calculations by calculating the efficiency EFF, defined as the <italic>s</italic>th root of the fraction of any 2 OFVs:</p>
<p><disp-formula id="disp-formula10-0091270010397731">
<label>(10)</label>
<mml:math display="block" id="math14-0091270010397731">
<mml:mrow>
<mml:mi>E</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>F</mml:mi>
<mml:mo>=</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>O</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>V</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>X</mml:mi>
<mml:mn>1</mml:mn>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mi>O</mml:mi>
<mml:mi>F</mml:mi>
<mml:mi>V</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>X</mml:mi>
<mml:mn>2</mml:mn>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>/</mml:mo>
<mml:mi>s</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula10-0091270010397731" xlink:href="10.1177_0091270010397731-eq10.tif"/>
</disp-formula></p>
<p>where <italic>s</italic> is the number of interesting parameters to be estimated in the model. The following efficiencies were evaluated:</p>
<list id="list1-0091270010397731" list-type="order">
<list-item><p>Efficiency of the optimized sparse designs including the prior compared with the original rich design without the prior for all 3 scenarios.</p></list-item>
<list-item><p>Efficiency of the optimized IV- or PO- dose–only designs compared with the same design setup with both doses (IVPO and POIV).</p></list-item>
<list-item><p>Efficiency of the reduced sample designs compared with the optimized design with 3 samples/dose or 6 samples total for the example of the CL and F scenario.</p></list-item>
</list>
<p>Note that when the OFV<sub>Ds</sub> criterion is used then this efficiency in <xref ref-type="disp-formula" rid="disp-formula9-0091270010397731">Equation 9</xref> is a D<sub>s</sub> efficiency. For the comparisons to the original design, the transformations of the EBEs to fixed effects and the D/D<sub>s</sub>-optimality criterion was applied here as well. The FIM<sub>MAP</sub> was computed for this case similar to <xref ref-type="disp-formula" rid="disp-formula3-0091270010397731">Equation 3</xref>, but without the prior information:</p>
<p><disp-formula id="disp-formula11-0091270010397731">
<label>(11)</label>
<mml:math display="block" id="math15-0091270010397731">
<mml:mrow>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>M</mml:mi>
<mml:mrow>
<mml:mi>M</mml:mi>
<mml:mi>A</mml:mi>
<mml:mi>P</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mn>1</mml:mn>
<mml:mrow>
<mml:mn>77</mml:mn>
</mml:mrow>
</mml:mfrac>
<mml:munderover>
<mml:mstyle displaystyle="true" mathsize="140%">
<mml:mo>∑</mml:mo>
</mml:mstyle>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mn>77</mml:mn>
</mml:mrow>
</mml:munderover>
<mml:mi>F</mml:mi>
<mml:mi>I</mml:mi>
<mml:mi>M</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>X</mml:mi>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>Θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula11-0091270010397731" xlink:href="10.1177_0091270010397731-eq11.tif"/>
</disp-formula></p>
<p>that is, without a population model, this gives the average expected precision for a new individual.</p>
<p>Furthermore, the original design was highly variable regarding the time between the 2 occasions with the 2 different formulations for each patient, which underwent pretransplant monitoring. Because this could not be reconstructed for the comparison with the new optimal designs, a washout period of 48 hours after the first dose (IV) was used in the calculations to mimic the separation of the 2 doses in the original design.</p>
</sec>
<sec id="section9-0091270010397731">
<title>Sampling and Dose Windows</title>
<p>Sampling windows for the optimal designs were defined based on practical considerations by rounding to the next half or full hour before and after the optimal sampling time, or stopping/starting the window just before/after the t<sub>2nd dose</sub> or in between 2 very close samples. The efficiency for 100 designs with uniformly chosen sampling times within these windows (same samples for all 77 individuals) were then calculated and the mean EFF was reported.</p>
<p>Additionally, the optimized Dose<sub>IV</sub> was rounded down and up to the closest half or full milligram dose for each design and assessed together with the sampling windows. The Dose<sub>PO</sub> was consequently adjusted as per 10 mg/kg - Dose<sub>IV_rounded</sub>. Subsequently, if, for example, the Dose<sub>IV</sub> was rounded up, the D<sub>inf</sub> had to be adjusted to result in a maximum infusion rate of 0.75 mg/kg/h. Again, the efficiency for 100 designs with uniformly chosen sampling times within the previously mentioned windows were calculated and the mean efficiency was reported when either rounding the Dose<sub>IV</sub> down or up.</p>
</sec>
</sec>
<sec id="section10-0091270010397731" sec-type="results">
<title>Results</title>
<sec id="section11-0091270010397731">
<title>Optimized Pretransplant Monitoring Designs</title>
<p>Optimized sparse pretransplant monitoring designs are presented in <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>. Both IVPO or POIV designs were considered for all 3 scenarios described previously (CL and F, MAP 6, MAP all). For each case, multiple design variables were optimized (xt<sub>IV</sub>, xt<sub>PO</sub>, n<sub>IV</sub>, n<sub>PO</sub>, t<sub>2nd dose</sub>, Dose<sub>IV</sub>, Dose<sub>PO</sub>, D<sub>inf</sub>).</p>
<table-wrap id="table1-0091270010397731" position="float">
<label>Table I</label>
<caption>
<p>Optimal Design Results for the IVPO and POIV Designs Under 3 Scenarios (CL and F, MAP 6, MAP All), Original Design Values for These Scenarios as Well as the Used Priors for Comparison<sup><xref ref-type="table-fn" rid="table-fn2-0091270010397731">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0091270010397731" xlink:href="10.1177_0091270010397731-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="3">IVPO</th>
<th align="center" colspan="3">POIV</th>
<th align="center" colspan="3">Original Design</th>
<th/>
</tr>
<tr>
<th align="left" colspan="2">Design</th>
<th align="center">CL and F</th>
<th align="center">MAP 6</th>
<th align="center">MAP All</th>
<th align="center">CL and F</th>
<th align="center">MAP 6</th>
<th align="center">MAP All</th>
<th align="center">CL and F</th>
<th align="center">MAP 6</th>
<th align="center">MAP All</th>
<th align="center">Priors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sampling times</td>
<td>TAD/TAI xt<sub>IV</sub>, h</td>
<td>1.92/0.86<break/>3.60/2.54<break/>3.60/2.54</td>
<td>2.34/0.54<break/>3.84/2.04<break/>3.84/2.04</td>
<td>2.80/0.5<break/>34.40/2.1<break/>34.40/2.13</td>
<td>0.01/-<break/>3.12/0.85<break/>3.20/0.93</td>
<td>0.00/-<break/>5.56/3.71<break/>5.56/3.71</td>
<td>0.06/-<break/>4.62/3.08<break/>4.62/3.08</td>
<td>0, 2, 4, 5, 6, 7, 8, 10, 13, 15, 20, 28</td>
<td>0, 2, 4, 5, 6, 7, 8, 10, 13, 15, 20, 28</td>
<td>0, 2, 4, 5, 6, 7, 8, 10, 13, 15, 20, 28</td>
<td>-</td>
</tr>
<tr>
<td/>
<td>TAD xt<sub>PO</sub>, h</td>
<td>0.70<break/>3.82<break/>4.38</td>
<td>0.18<break/>1.41<break/>4.13</td>
<td>0.19<break/>1.23<break/>3.55</td>
<td>0.64<break/>1.12<break/>4.64</td>
<td>0.12<break/>0.12<break/>2.40</td>
<td>0.09<break/>1.04<break/>3.36</td>
<td>0, 1, 2, 3, 4, 6, 9, 12, 16, 24</td>
<td>0, 1, 2, 3, 4, 6, 9, 12, 16, 24</td>
<td>0, 1, 2, 3, 4, 6, 9, 12, 16, 24</td>
<td/>
</tr>
<tr>
<td>Other optimized design variables</td>
<td>Dose<sub>IV</sub>, mg/kgDose<sub>PO</sub>, mg/kgD<sub>inf</sub>, h t<sub>2nd</sub> <sub>dose</sub>, h</td>
<td>0.78<break/>9.22<break/>1.06<break/>3.62</td>
<td>1.26<break/>8.74<break/>1.80<break/>3.87</td>
<td>1.41<break/>8.59<break/>2.27<break/>4.45</td>
<td>1.70<break/>8.31<break/>2.27<break/>4.64</td>
<td>1.38<break/>8.62<break/>1.85<break/>2.44</td>
<td>1.14<break/>8.86<break/>1.54<break/>3.38</td>
<td>3<break/>10<break/>4<break/>-</td>
<td>3<break/>10<break/>4<break/>-</td>
<td>3<break/>10<break/>4<break/>-</td>
<td/>
</tr>
<tr>
<td>Comparison with original designs</td>
<td>Number of parameters, s</td>
<td>2</td>
<td>6</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td>8</td>
<td/>
</tr>
<tr>
<td/>
<td>OFV value</td>
<td>2.38E + 3</td>
<td>1.25E + 8</td>
<td>1.24E + 10</td>
<td>2.48E + 3</td>
<td>2.30E + 8</td>
<td>2.61E + 10</td>
<td>9.72E + 3</td>
<td>1.58E + 10</td>
<td>7.60E + 12</td>
<td/>
</tr>
<tr>
<td/>
<td>EFF</td>
<td>49.47%</td>
<td>44.63%</td>
<td>44.85%</td>
<td>50.53%</td>
<td>49.39%</td>
<td>49.21%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td/>
</tr>
<tr>
<td>SD</td>
<td><italic>CL<sub>i</sub></italic></td>
<td>0.10<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.09<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.09<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.11<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.13<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.13<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.07<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.07<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.07<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.17</td>
</tr>
<tr>
<td/>
<td>(V2 Q4 V4)<sub>i</sub></td>
<td>0.33</td>
<td>0.33<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.33<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.38</td>
<td>0.36<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.36<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.54</td>
<td>0.54<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.54<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.40</td>
</tr>
<tr>
<td/>
<td><italic>ka<sub>i</sub></italic></td>
<td>0.19</td>
<td>0.19<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.20<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.18</td>
<td>0.18<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.18<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.21</td>
<td>0.21<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.21<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.35</td>
</tr>
<tr>
<td/>
<td><italic>F<sub>i</sub></italic><sup><xref ref-type="table-fn" rid="table-fn4-0091270010397731">c</xref></sup></td>
<td>0.11<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.11<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.08<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.08<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.08<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.23</td>
</tr>
<tr>
<td/>
<td>V3<sub>i</sub><sup><xref ref-type="table-fn" rid="table-fn3-0091270010397731">b</xref></sup></td>
<td>0.41</td>
<td>0.41<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.41<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.40</td>
<td>0.37<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.37<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.26</td>
<td>0.26<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.26<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.42</td>
</tr>
<tr>
<td/>
<td><italic>Q</italic>3<sub><italic>i</italic></sub></td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.31</td>
<td>0.27<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.27<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.18</td>
<td>0.18<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.18<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.32</td>
</tr>
<tr>
<td/>
<td>RUV IV<sub>i</sub></td>
<td>0.30</td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.30</td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.20</td>
<td>0.20</td>
<td>0.20<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.43</td>
</tr>
<tr>
<td/>
<td>RUV PO<sub>i</sub></td>
<td>0.32</td>
<td>0.32</td>
<td>0.32<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.32</td>
<td>0.32</td>
<td>0.32<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.22</td>
<td>0.22</td>
<td>0.22<sup><xref ref-type="table-fn" rid="table-fn5-0091270010397731">d</xref></sup></td>
<td>0.52</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010397731">
<p>IV, intravenous; PO, oral; D<sub>inf</sub>, duration of infusion; t<sub>2nd</sub> <sub>dose</sub>, start time of second dose; OFV, objective function value; EFF, efficiency; SD θ<sub>
<italic>i,k</italic></sub>, average expected standard deviation for the parameter k in a new patient; TAD, time after dose; TAI, time after end of infusion; h, hours; s, number of parameters; SD, standard deviation.</p>
</fn>
<fn id="table-fn2-0091270010397731">
<label>a.</label>
<p>TAD sampling times for the second dose are reported with respect to the t<sub>2nd</sub> <sub>dose</sub>.</p>
</fn>
<fn id="table-fn3-0091270010397731">
<label>b.</label>
<p>Parameter nomenclature has been adapted from the publication of the population model.<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup></p>
</fn>
<fn id="table-fn4-0091270010397731">
<label>c.</label>
<p><italic>SD<sub>F<sub>i</sub></sub></italic> ~ F*(1-F)*<italic>SD<sub>EBE(F<sub>i</sub>)</sub></italic>.</p>
</fn>
<fn id="table-fn5-0091270010397731">
<p><sup>d.</sup> Parameters of interest.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As visible in <xref ref-type="fig" rid="fig2-0091270010397731">Figure 2</xref> and <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>, the IVPO designs all have samples in the elimination phase after the infusion dose, xt<sub>IV</sub>, between 0.5 and 1 hour after the end of the infusion and 2 clustered samples just before the start of the PO dose. The time of administration of the PO dose is also similar for all IVPO designs, around half way (4 hours) through the monitoring schedule. However, the clearance However, the CL and F scenario varies greatly from the other 2 designs regarding the samples after the Dose<sub>PO</sub>.</p>
<fig id="fig2-0091270010397731" position="float">
<label>Figure 2.</label>
<caption>
<p>The figure shows optimal designs for the IVPO (left) and the POIV (right) settings for all 3 scenarios of interesting parameters. The optimal sampling times are shown as black dots at the times presented in <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>. Sampling windows (gray shaded areas) and concentration-time profiles for the up/down rounded Dose<sub>IV</sub> scenario (gray dashed profiles) are shown. Vertical gray dashed lines represent borders between adjoining sampling windows.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397731-fig2.tif"/>
</fig>
<p>The optimal designs under the POIV setting for the 3 scenarios are also relatively similar to one another, with samples for the PO dose just before the start of the IV infusion and samples for the IV straight after the start of the infusion and at the very end of the observation period. However, the start times of the Dose<sub>IV</sub> and the early xt<sub>PO</sub> times are very different for all 3 scenarios.</p>
<p>When comparing the IVPO and POIV scenarios we see that Dose<sub>PO</sub> are very similar in both. The Dose<sub>IV</sub> and D<sub>inf</sub> are quite different between scenarios; however, all combinations resulted in infusion rates just below the 0.75 mg/kg/h restriction, with the exception being the IVPO design under the MAP all scenario. Here, the optimal infusion duration resulted in a lower infusion rate of 0.62 mg/kg/h compared with the other optimal designs. Regarding the Dose<sub>order</sub>, the efficiency indicates that the POIV scenario is slightly more efficient than the IVPO, but the differences are marginal in terms of expected parameter uncertainty (parameter SD in <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>). For all designs, the expected parameter uncertainty is relatively low for most of the parameters, in particular, for the main parameters of interest CL and F.</p>
</sec>
<sec id="section12-0091270010397731">
<title>Comparison of Optimized Designs With Original Design and Priors</title>
<p>To evaluate the loss in efficiency and also the predictability of the individual parameter estimates with the reduced optimal designs compared with the previous rich design, the efficiency (EFF) was calculated. Here, the EFF reduction was found to be between 50% and 55% (<xref ref-type="table" rid="table1-0091270010397731">Table I</xref>). Furthermore, the expected SD for the parameters under the optimal designs can be compared with these original designs as well as with the priors. Comparison with the original design shows that the SDs for CL<sub>i</sub>, ka<sub>i</sub>, and F<sub>i</sub> are only slightly worse under the new sparse designs, but still very small. Furthermore, the future individual parameters for (V2 V4 Q4)<sub>i</sub> are much better predicted under the new designs than with the original. The optimal sparse designs provided worse expected SDs for V3<sub>i</sub>, Q3<sub>i</sub>, and the RUVs<sub>i</sub>, however, these parameters might not be crucial for a precise posttransplant dose prediction. Compared with the prior information, the SDs of the individual parameters for the sparse designs were reduced by between 5% and 48%, with CL<sub>i</sub> being reduced by 23% to 47% and F<sub>i</sub> by 48% (<xref ref-type="table" rid="table1-0091270010397731">Table I</xref>).</p>
</sec>
<sec id="section13-0091270010397731">
<title>Designs With Only One Dose</title>
<p>The efficiencies of the IV and PO only optimized designs were compared to the IVPO and POIV optimized designs are shown in <xref ref-type="table" rid="table2-0091270010397731">Table II</xref>. As expected, the optimal PO dose under any of the 3 scenarios was estimated to be 10 mg/kg, which was the upper limit of the searched dose range. Administration of only the PO dose resulted in a 7% to 32% loss of EFF on average per parameter. This result is also reflected by the expected SDs of the parameters. Comparison of the SDs from the IVPO and POIV designs (<xref ref-type="table" rid="table1-0091270010397731">Table I</xref>) show that the expected SDs are only slightly higher (between 1%-38% for CL<sub>i</sub>) with the PO- dose–only designs (<xref ref-type="table" rid="table2-0091270010397731">Table II</xref>). A comparison of the expected SDs for CL<sub>i</sub> and F<sub>i</sub> for the PO, IVPO, and POIV design settings are shown in <xref ref-type="fig" rid="fig3-0091270010397731">Figure 3</xref>. All methods are seen to produce low uncertainty in parameter estimates.</p>
<table-wrap id="table2-0091270010397731" position="float">
<label>Table II</label>
<caption>
<p>Optimal Reduced Designs With the Administration of an Oral Dose or an Intravenous Dose Only</p>
</caption>
<graphic alternate-form-of="table2-0091270010397731" xlink:href="10.1177_0091270010397731-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="3">PO Only</th>
<th align="center" colspan="3">IV Only</th>
</tr>
<tr>
<th align="left" colspan="2">Design</th>
<th align="center">CL and F</th>
<th align="center">MAP 6</th>
<th align="center">MAP All</th>
<th align="center">F</th>
<th align="center">MAP 4</th>
<th align="center">MAP All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimized design variables</td>
<td>TAD, hDose<sub>PO</sub>, mg/kgDose<sub>IV</sub>, mg/kgD<sub>inf</sub>, h</td>
<td>0.80<break/>2.92<break/>8<break/>10<break/>–<break/>–</td>
<td>0.15<break/>3.10<break/>8.00<break/>10.00<break/>–<break/>–</td>
<td>0.15<break/>3.10<break/>8.00<break/>10.00<break/>–<break/>–</td>
<td>4.88<break/>4.88<break/>8.00<break/>–<break/>3.00<break/>4.00</td>
<td>4.56<break/>8.00<break/>8.00<break/>–<break/>2.98<break/>4.00</td>
<td>2.96<break/>4.96<break/>8.00<break/>–<break/>1.82<break/>2.43</td>
</tr>
<tr>
<td>Comparison to other optimized designs</td>
<td>Number of  parameters, sOFV valueEFF (test/IVPO)EFF (test/POIV)</td>
<td>21.14E + 3<break/>69.2%<break/>67.8%</td>
<td>68.30E + 7<break/>93.4%<break/>84.4%</td>
<td>78.06E + 8<break/>93.4%<break/>93.4%</td>
<td>11.19E + 2<break/>243.2%<break/>238.0%</td>
<td>49.26E + 4<break/>78.0%<break/>70.5%</td>
<td>51.07E + 6<break/>87.9%<break/>80.1%</td>
</tr>
<tr>
<td>SD</td>
<td><italic>CL<sub>i</sub></italic></td>
<td>0.15<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.15<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.15<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.09<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.09<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.09<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>(V2 Q4 V4)<sub>i</sub></td>
<td>0.39</td>
<td>0.38<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.38<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.37</td>
<td>0.36<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.35<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
</tr>
<tr>
<td/>
<td><italic>ka<sub>i</sub></italic></td>
<td>0.21</td>
<td>0.19<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.19<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td/>
<td><italic>F<sub>i</sub></italic><sup><xref ref-type="table-fn" rid="table-fn8-0091270010397731">b</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.12<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td/>
<td>V3<sub>i</sub></td>
<td>0.40</td>
<td>0.40<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.40<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.40</td>
<td>0.40<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.40<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
</tr>
<tr>
<td/>
<td><italic>Q</italic>3<sub><italic>i</italic></sub></td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td>0.29<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>RUV IV<sub>i</sub></td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>0.30</td>
<td>0.30</td>
<td>0.30<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
</tr>
<tr>
<td/>
<td>RUV PO<sub>i</sub></td>
<td>0.32</td>
<td>0.32</td>
<td>0.32<sup><xref ref-type="table-fn" rid="table-fn7-0091270010397731">a</xref></sup></td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0091270010397731">
<p>IV, intravenous; PO, oral; D<sub>inf</sub>, duration of infusion; OFV, objective function value; EFF, efficiency; SD θ<sub><italic>i,k</italic></sub>, average expected standard deviation for the parameter k in a new patient; TAD, time after dose; h, hours; s, number of parameters; SD, standard deviation.</p>
</fn>
<fn id="table-fn7-0091270010397731">
<label>a.</label>
<p>SDs of parameters of interest.</p>
</fn>
<fn id="table-fn8-0091270010397731">
<label>b.</label>
<p><italic>SD<sub>F<sub>i</sub></sub></italic> ~ F*(1-F)*<italic>SD<sub>EBE(F<sub>i</sub>)</sub></italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig3-0091270010397731" position="float">
<label>Figure 3.</label>
<caption>
<p>The figure shows expected standard deviations (SD) for clearance (CL<sub>i</sub>) (top) and bioavailability (F<sub>i</sub>) (bottom) under the IVPO, POIV, PO, IV, and original dosing schemes for the CL and F scenario.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397731-fig3.tif"/>
</fig>
<p>Similar comparisons and results can be seen for the designs with an IV dose only. Here, the highest dose (3 mg/kg) was chosen for 2 scenarios, and in all scenarios the D<sub>inf</sub> was estimated as 0.75 mg/kg/h (constrain maxima). The samples are to be taken 0.5 to 0.9 hours after the end of the infusion and at the end of the observation period. For the design under the MAP all setting, a sampling time after the end of the infusion, at 2.53 hours, was additionally found. Comparison of the SDs from the IV- dose–only design with the SDs from the IVPO and POIV designs (<xref ref-type="table" rid="table1-0091270010397731">Table I</xref>) show that the expected SDs are only slightly higher for some parameters with the IV- dose–only designs (<xref ref-type="table" rid="table2-0091270010397731">Table II</xref>), however, 2% to 30% better for the SD on CL. Overall, the PO- only design is better if the interest focuses on estimating F and CL, whereas the IV- only design should be preferred if the interest focuses on estimating CL.</p>
</sec>
<sec id="section14-0091270010397731">
<title>Sampling and Dose Windows</title>
<p>The optimized designs, including sampling windows and rounded doses, are graphically displayed as concentration-time profiles in <xref ref-type="fig" rid="fig2-0091270010397731">Figure 2</xref>. Rounding doses and setting windows around the sampling times provide for an uncomplicated implementation of the protocol in the clinic. The rounded doses are done to avoid administration errors. Rounding the Dose<sub>IV</sub> resulted in minimal changes for the Dose<sub>PO</sub> and minimal changes in the concentrations. From the simulations of 100 new designs with uniform samples within the sampling windows, a 2% to 8% efficiency loss was found compared to sampling at the exact optimal sampling times. Additional rounding of the IV dose for the IVPO designs down to 0.5 mg/kg/0.67 h and up to 1 mg/kg/1.34 h for the CL and F scenario, and down to 1 mg/kg/1.34 h and up to 1.5 mg/kg/2 h for the other 2 scenarios, resulted in a further minimal 1% to 3% efficiency reduction. For the IVPO design under the MAP all scenario the infusion duration was also adjusted for the dose windows to the maximum infusion rate of 0.75 mg/kg/h like all other designs. Note that the optimal infusion duration was found to be below 0.75 mg/kg/h and therefore, both dose window profiles are below the optimal dose profile in <xref ref-type="fig" rid="fig2-0091270010397731">Figure 2</xref>.</p>
<p>For the POIV designs, the doses were rounded down to 1.5 mg/kg/2 h and up to 2 mg/kg/2.67 h for the CL and F scenario, and down to 1 mg/kg/1.34 h and up to 1.5 mg/kg/2 h for the other 2 scenarios. This resulted in a similar further efficiency reduction of 1% to 4%. This minimal loss in efficiency has only a diminutive impact on the expected SDs and the performance of the optimal designs.</p>
</sec>
<sec id="section15-0091270010397731">
<title>Design Comparison for Designs With Less Samples</title>
<p>To demonstrate the influence of the sample intensity, further reduced optimal designs were investigated for the CL and F scenarios of the IVPO setting. Overall, this resulted in a further small trade-off in parameter precision (see <xref ref-type="table" rid="table3-0091270010397731">Table III</xref>) given the D<sub>s</sub> objective function value (OFV<sub>Ds</sub>) as a measure of informativeness and the efficiency reduction compared with the design with 6 samples in total. When the number of samples/dose was optimized simultaneously with the other design variables, the designs with unbalanced numbers of samples/dose were shown to be more informative. For these unbalanced designs it was found that with only 2 samples in total, an optimal design would not administer an IV dose (with Dose<sub>IV</sub> = 0, D<sub>inf</sub> = N/A, t<sub>2nd dose</sub> = 0). <xref ref-type="table" rid="table3-0091270010397731">Table III</xref> shows the influence of the reduction of samples on the SDs for CL and F. The changes on the SDs are relatively small for CL and F, however, largest for CL when different numbers of samples/dose are considered.</p>
<table-wrap id="table3-0091270010397731" position="float">
<label>Table III</label>
<caption>
<p>Results for the IVPO (CL and F) Design When Further Reducing the Number of Samples, Optimizations to the Left Include an Optimization for Samples per Dose (Unbalanced Design), Optimizations to the Right Have Equal Numbers of Samples per Dose (Balanced Design)<sup><xref ref-type="table-fn" rid="table-fn10-0091270010397731">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table3-0091270010397731" xlink:href="10.1177_0091270010397731-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="5">Different Number of Samples/Dose</th>
<th align="center" colspan="3">50% of Samples/Dose</th>
</tr>
<tr>
<th align="left" colspan="2">Number of Samples (total)</th>
<th align="center">6</th>
<th align="center">5</th>
<th align="center">4</th>
<th align="center">3</th>
<th align="center">2</th>
<th align="center">6 (optimized IVPO ‘CL &amp;F’ design)</th>
<th align="center">4</th>
<th align="center">2</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2">TAD xt<sub>IV</sub>, h</td>
<td>2.88</td>
<td>2.88</td>
<td>3.68</td>
<td>4.04</td>
<td align="center">–</td>
<td>1.92</td>
<td>2.72</td>
<td>4.88</td>
</tr>
<tr>
<td/><td/>
<td>3.12</td>
<td>4.16</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>3.6</td>
<td>5.76</td>
<td align="center">–</td>
</tr>
<tr>
<td/><td/>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td>3.6</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td colspan="2">TAD xt<sub>PO</sub>, h</td>
<td>0.80</td>
<td>0.77</td>
<td>0.65</td>
<td>1.24</td>
<td>1.06</td>
<td>0.70</td>
<td>2.20</td>
<td>3.20</td>
</tr>
<tr>
<td/><td/>
<td>1.28</td>
<td>3.81</td>
<td>3.45</td>
<td>3.32</td>
<td>4.95</td>
<td>3.82</td>
<td>2.20</td>
<td align="center">–</td>
</tr>
<tr>
<td/><td/>
<td>4.24</td>
<td>3.81</td>
<td>3.61</td>
<td align="center">–</td>
<td align="center">–</td>
<td>4.38</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td/><td/>
<td>4.24</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td colspan="2">Dose <sub>IV</sub>, mg/kg</td>
<td>1.17</td>
<td>1.32</td>
<td>1.68</td>
<td>2.04</td>
<td>0.00</td>
<td>0.780</td>
<td>1.410</td>
<td>2.670</td>
</tr>
<tr>
<td colspan="2">Dose<sub>PO</sub>, mg/kg</td>
<td>8.83</td>
<td>8.68</td>
<td>8.32</td>
<td>7.96</td>
<td>10.00</td>
<td>9.22</td>
<td>8.59</td>
<td>7.33</td>
</tr>
<tr>
<td colspan="2">D<sub>inf</sub>, h</td>
<td>1.58</td>
<td>1.83</td>
<td>2.32</td>
<td>2.81</td>
<td align="center">–</td>
<td>1.06</td>
<td>1.88</td>
<td>3.56</td>
</tr>
<tr>
<td colspan="2">t<sub>2nd</sub> <sub>dose (PO)</sub>, h</td>
<td>3.76</td>
<td>4.19</td>
<td>4.39</td>
<td>4.68</td>
<td>0.00</td>
<td>3.62</td>
<td>5.80</td>
<td>5.80</td>
</tr>
<tr>
<td colspan="2">OFV<sub>DS</sub></td>
<td>3177.35</td>
<td>2616.22</td>
<td>1827.27</td>
<td>1411.38</td>
<td>832.67</td>
<td>2377.72</td>
<td>1462.65</td>
<td>762.92</td>
</tr>
<tr>
<td colspan="2">EFF</td>
<td>100.0%</td>
<td>90.7%<sup><xref ref-type="table-fn" rid="table-fn11-0091270010397731">b</xref></sup></td>
<td>75.8%<sup><xref ref-type="table-fn" rid="table-fn11-0091270010397731">b</xref></sup></td>
<td>66.6%<sup><xref ref-type="table-fn" rid="table-fn11-0091270010397731">b</xref></sup></td>
<td>51.2%<sup><xref ref-type="table-fn" rid="table-fn11-0091270010397731">b</xref></sup></td>
<td>100.0%</td>
<td>78.4%</td>
<td>56.6%</td>
</tr>
<tr>
<td><italic>SD</italic></td>
<td><italic>CL<sub>i</sub></italic></td>
<td>0.10</td>
<td>0.10</td>
<td>0.11</td>
<td>0.11</td>
<td>0.15</td>
<td>0.10</td>
<td>0.10</td>
<td>0.11</td>
</tr>
<tr>
<td/>
<td>(V2 Q4 V4)<sub>i</sub></td>
<td>0.37</td>
<td>0.36</td>
<td>0.39</td>
<td>0.39</td>
<td>0.39</td>
<td>0.33</td>
<td>0.36</td>
<td>0.39</td>
</tr>
<tr>
<td/>
<td><italic>ka<sub>i</sub></italic></td>
<td>0.18</td>
<td>0.19</td>
<td>0.21</td>
<td>0.26</td>
<td>0.23</td>
<td>0.19</td>
<td>0.31</td>
<td>0.33</td>
</tr>
<tr>
<td/>
<td><italic>F<sub>i</sub></italic>*</td>
<td>0.11</td>
<td>0.11</td>
<td>0.12</td>
<td>0.12</td>
<td>0.12</td>
<td>0.11</td>
<td>0.12</td>
<td>0.14</td>
</tr>
<tr>
<td/>
<td>V3<sub>i</sub></td>
<td>0.41</td>
<td>0.41</td>
<td>0.41</td>
<td>0.41</td>
<td>0.42</td>
<td>0.41</td>
<td>0.41</td>
<td>0.41</td>
</tr>
<tr>
<td/>
<td><italic>Q</italic>3<sub><italic>i</italic></sub></td>
<td>0.30</td>
<td>0.31</td>
<td>0.31</td>
<td>0.31</td>
<td>0.32</td>
<td>0.30</td>
<td>0.30</td>
<td>0.31</td>
</tr>
<tr>
<td/>
<td>RUV IV<sub>i</sub></td>
<td>0.30</td>
<td>0.30</td>
<td>0.33</td>
<td>0.33</td>
<td>0.37</td>
<td>0.30</td>
<td>0.33</td>
<td>0.37</td>
</tr>
<tr>
<td/>
<td>RUV PO<sub>i</sub></td>
<td>0.32</td>
<td>0.36</td>
<td>0.36</td>
<td>0.42</td>
<td>0.42</td>
<td>0.32</td>
<td>0.36</td>
<td>0.42</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0091270010397731">
<p>IV, intravenous; PO, oral; D<sub>inf</sub>, duration of infusion; t<sub>2nd</sub> <sub>dose (po)</sub>, start time of second dose (oral dose); OFV<sub>DS</sub> objective function value; EFF, efficiency; SD θ<sub><italic>i,k</italic></sub>, average expected standard deviation for the parameter k in a new patient; TAD, time after dose; h, hours; s, number of parameters; SD, standard deviation.</p>
</fn>
<fn id="table-fn10-0091270010397731">
<label>a.</label>
<p>TAD sampling times for PO dose are reported with respect to the t<sub>2nd</sub> <sub>dose</sub>.</p>
</fn>
<fn id="table-fn11-0091270010397731">
<label>b.</label>
<p><italic>SD<sub>Fi</sub></italic> ~ F*(1-F)*<italic>SD<sub>EBE(F<sub>i</sub>)</sub></italic></p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Additionally, it can be seen that the PO dose is more informative than the IV dose. This can be seen by the larger amount of samples being allocated after the PO dose in the reduced designs. It should be noted that for the design with only 2 samples and an optimization performed on the samples/dose, the IVPO design collapsed to a design with an oral dose only.</p>
</sec>
</sec>
<sec id="section16-0091270010397731" sec-type="discussion">
<title>Discussion</title>
<p>The aim of this work was to identify a global design for monitoring ciclosporin in all future transplant patients that would optimize the precision of individual parameter estimates. A rich pretransplant PK design was reduced from 22 to 6 samples per patient in total, and the observation period was reduced from 2 separate occasions with more than a 24-hour observation time on each occasion to a single occasion of 8 hours of total observation time. These simplifications allow for easier clinical implementation with a very small loss in the estimation precision of the individual parameters of interest for future dose prediction (CL<sub>i</sub> and F<sub>i</sub>, see <xref ref-type="fig" rid="fig3-0091270010397731">Figure 3</xref>) despite the integration of clinical restrictions. The use of sampling and dose windows made the optimal designs clinically feasible with again only a minimum loss of efficiency. Further reductions of the optimal designs were also explored and are available to use.</p>
<p>We believe that this article provides a guide, with a combination of optimal design methods, which can be readily implemented in existing software tools<sup><xref ref-type="bibr" rid="bibr13-0091270010397731">13</xref></sup> to improve any monitoring procedure. Previously, others have suggested using a Bayesian information criteria to improve TDM designs.<sup><xref ref-type="bibr" rid="bibr9-0091270010397731">9</xref>,<xref ref-type="bibr" rid="bibr10-0091270010397731">10</xref></sup> However, to our knowledge, this has never been used to optimize design variables other than sampling times, and the methods were not implemented in publically available optimal design software programs. The methods presented here provide both. Methods such as the optimization of several design variables simultaneously<sup><xref ref-type="bibr" rid="bibr14-0091270010397731">14</xref></sup> to minimize efficiency loss, the use of a population model<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> as prior information to minimize the uncertainty on the MAP estimated individual parameters, incorporating the uncertainty on the individual level using E-family techniques,<sup><xref ref-type="bibr" rid="bibr9-0091270010397731">9</xref></sup> and the use of the D<sub>s</sub>-optimality criterion were applied and used in PopED.<sup><xref ref-type="bibr" rid="bibr13-0091270010397731">13</xref></sup></p>
<p>The prior information from the population model was included in the design calculations using a combination of several new features. First, the EBEs given from the population analysis by Fanta et al were used as a discrete sampling distribution of possible future individual parameters. This was done by using the E-family optimal design with discrete parameter distributions corresponding to the 77 discrete sets of EBE values of the former patients. In addition, each set of EBE values were coupled to the previous patient’s weights enabling us to retain the correlation between all of the parameters and the covariate. This method was chosen because the former patients represent, up to the publication of Fanta et al,<sup><xref ref-type="bibr" rid="bibr2-0091270010397731">2</xref></sup> the entire Finish pediatric transplant population. We assume in this work that this group will likely represent the future population of pediatric renal transplant patients in Finland reasonably well. An alternative sampling strategy of future individual parameter values could have been from multivariate normal distributions instead of discrete distributions. However, this method could lead to extreme individual PK profiles that are unlikely to appear in reality. Furthermore, assumptions on an empirical weight distribution would have been necessary. We believe our method also reduced errors in case of a covariate model misspecification. However, for other design optimizations, other options should not be ruled out.</p>
<p>Another feature used here was the inclusion of prior information on the individual level. The priors used here were the BSV from the population model. Overall, the SDs for all MAP estimated individual parameters could be reduced compared with the priors, with the important parameters, CL<sub>i</sub> and F<sub>i</sub>, being reduced by 40% or more. Differences in the expected SDs for CL<sub>i</sub> and F<sub>i</sub> are negligible comparing the IVPO and POIV optimal designs to the original design (<xref ref-type="fig" rid="fig3-0091270010397731">Figure 3</xref>). This emphasizes the importance of incorporating priors from the population model for any future test design. Furthermore, increases in the SDs when using the designs with only an oral dose were relatively small compared with the optimized designs with both doses, because of the utilization of these priors. In <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>, it is noticeable that the expected SD for (V2 Q4 V4)<sub>i</sub> under the original design is larger than the prior for the same parameters. We believe that this is because the original design used by us for comparison is not exactly identical with the one that was actually executed in the clinic (eg, protocol times used here compared with exact times), and the average expected SDs of the MAP estimated individual parameters are not exactly equivalent to the square root of the variances of the population mean.</p>
<p>A second comparison of the design was done using OFVs to calculate the EFF. The 2 alternatives of comparisons to the original rich design, described in the article by Fanta et al, were originally suggested as a comparison with what was originally done without considering priors or a comparison with the original design with the utilization of priors. Even though the first alternative might be considered unfair, the second option was not regarded as reasonable because there will be no continuation of the original design. Therefore, the comparisons with what was done previously was chosen here rather then the comparisons with what would never be done. The EFF reduction of 50% on average for the optimal test designs to the original design was expected because of the major reduction of the design. However, this resulted only in a minimal reduction of the predictability of the model.</p>
<p>Diagnostic designs are performed to confirm the current dose to be within a therapeutic range or to learn how to change and predict a new dose. During chronic IV and PO dosing, the parameters needed for this prediction are CL<sub>i</sub> and F<sub>i</sub>, as described above; therefore, the focus here was to primarily estimate CL<sub>i</sub> and F<sub>i</sub> with high precision. The D<sub>s</sub> criterion was considered the most appropriate method to emphasize CL<sub>i</sub> and F<sub>i</sub> because this criterion preserves the correlation between all parameters of the model, which is not done when “fixing” the uninteresting parameters, which are then not considered in the FIM calculations. As previously suggested, the D<sub>s-</sub> optimality criterion<sup><xref ref-type="bibr" rid="bibr12-0091270010397731">12</xref>,<xref ref-type="bibr" rid="bibr19-0091270010397731">19</xref></sup> has been adapted in our implementation. In this work, we did not notice large differences between using the D<sub>s</sub> or the D criterion in the outcome of the designs between the 3 scenarios. However, we believe from a theoretical point of view this was the right method to choose. Several factors might have caused these similarities, such as the relatively rich design, the strong priors, and the correlation between the precision of CL<sub>i</sub> and F<sub>i</sub>, and the other parameters are very low or noninfluential for the design (see <xref ref-type="disp-formula" rid="disp-formula7-0091270010397731">Equation 7</xref>). It is therefore expected that in studies where the prior information is not as strong and the designs are sparser, the D<sub>s</sub> criterion would be more effective. As expected, the SDs for CL<sub>i</sub> and F<sub>i</sub> are lowest under the CL and F scenario (see <xref ref-type="table" rid="table1-0091270010397731">Table I</xref>).</p>
<p>No large differences were found when evaluating the dose order (Dose<sub>order</sub>). The POIV design setup might be favored given the possibility to allow for a similar fasting routine before the PO dosing as in the original design. The differences in the SDs for the main CL and F scenario (SD<sub>CL</sub> = 0.095 for IVPO vs 0.112 for POIV, and SD<sub>F</sub> = 0.114 in both cases) were found to be minimal in regard to the Dose<sub>order</sub>. Furthermore, the POIV might also be preferable for safety reasons, because the highest ciclosporin concentrations are obtained after the first (PO) dose and therefore the patients can be observed for a longer time after the PO dose. The POIV scenario may also limit the possibility of concentrations measured below the limit of detection in clinically used assays (5 µg/L) more than with the IVPO design. Instead, the IVPO design would allow for the administration of the intravenous dose as the first procedure in the morning. Both IVPO and POIV designs were found to have a sufficient amount of time between sampling windows to allow for other procedures during the same 1-day clinic visit.</p>
<p>Finally, we would like to highlight that the designs presented here were optimized for several design variables simultaneously. It is expected that a sequential optimization procedure would result in less optimal designs.<sup><xref ref-type="bibr" rid="bibr14-0091270010397731">14</xref></sup></p>
<p>Currently, the predictability of the pretransplant ciclosporin PK to the posttransplant ciclosporin PK is under investigation by Fanta et al. The group is also investigating the practicalities of using a combination compared with using only IV or PO administration. The results of theses investigations will determine which type of reduced design will be incorporated into the pretransplant protocol.</p>
</sec>
</body>
<back>
<ack><p>We would like to acknowledge Siv Jönsson for the contribution of the original model, and for discussions on setting restrictions for the design calculations and on the results of the optimal designs. Dr Hennig, Mr Nyberg, Dr Hooker, and Dr Karlsson have contributed equally to this article.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
<fn fn-type="supplementary-material">
<p>Online appendices for this article are available at <ext-link ext-link-type="uri" xlink:href="http://jcp.sagepub.com/supplemental/">http://jcp.sagepub.com/supplemental/</ext-link>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010397731">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoppu</surname><given-names>K</given-names></name>
<name><surname>Koskimies</surname><given-names>O</given-names></name>
<name><surname>Holmberg</surname><given-names>C</given-names></name>
<name><surname>Hirvisalo</surname><given-names>EL</given-names></name>
</person-group>. <article-title>Pharmacokinetically determined cyclosporine dosage in young children</article-title>. <source>Pediatr Nephrol</source>. <year>1991</year>;<volume>5</volume>:<fpage>1</fpage>-<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010397731">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fanta</surname><given-names>S</given-names></name>
<name><surname>Jonsson</surname><given-names>S</given-names></name>
<name><surname>Backman</surname><given-names>JT</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Hoppu</surname><given-names>K</given-names></name>
</person-group>. <article-title>Developmental pharmacokinetics of ciclosporin—a population pharmacokinetic study in pediatric renal transplant candidates</article-title>. <source>Br J Clin Pharmacol</source>. <year>2007</year>;<volume>64</volume>:<fpage>772</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010397731">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Savic</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Diagnosing model diagnostics</article-title>. <source>Clin Pharmacol Ther</source>. <year>2007</year>;<volume>82</volume>:<fpage>17</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010397731">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dansirikul</surname><given-names>C</given-names></name>
<name><surname>Staatz</surname><given-names>CE</given-names></name>
<name><surname>Duffull</surname><given-names>SB</given-names></name>
<name><surname>Taylor</surname><given-names>PJ</given-names></name>
<name><surname>Lynch</surname><given-names>SV</given-names></name>
<name><surname>Tett</surname><given-names>SE</given-names></name>
</person-group>. <article-title>Sampling times for monitoring tacrolimus in stable adult liver transplant recipients</article-title>. <source>Ther Drug Monit</source>. <year>2004</year>;<volume>26</volume>:<fpage>593</fpage>-<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010397731">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>BS</given-names></name>
<name><surname>Fleming</surname><given-names>DH</given-names></name>
<name><surname>Jeyaseelan</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>A limited sampling strategy for tacrolimus in renal transplant patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2008</year>;<volume>66</volume>:<fpage>467</fpage>-<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010397731">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langers</surname><given-names>P</given-names></name>
<name><surname>Cremers</surname><given-names>SC</given-names></name>
<name><surname>den Hartigh</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2007</year>;<volume>26</volume>:<fpage>1447</fpage>-<lpage>1454</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010397731">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hennig</surname><given-names>S</given-names></name>
<name><surname>Waterhouse</surname><given-names>TH</given-names></name>
<name><surname>Bell</surname><given-names>SC</given-names></name>
<etal/>
</person-group>. <article-title>A D-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients</article-title>. <source>Br J Clin Pharmacol</source>. <year>2007</year>;<volume>63</volume>:<fpage>438</fpage>-<lpage>450</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010397731">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>B</given-names></name>
<name><surname>Duffull</surname><given-names>SB</given-names></name>
</person-group>. <article-title>Prospective evaluation of a D-optimal designed population pharmacokinetic study</article-title>. <source>J Pharmacokin Pharmacodyn</source>. <year>2003</year>;<volume>30</volume>:<fpage>145</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010397731">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merle</surname><given-names>Y</given-names></name>
<name><surname>Mentre</surname><given-names>F</given-names></name>
</person-group>. <article-title>Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1999</year>;<volume>27</volume>:<fpage>85</fpage>-<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010397731">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Merle</surname><given-names>Y</given-names></name>
<name><surname>Mentre</surname><given-names>F</given-names></name>
</person-group>. <article-title>Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model</article-title>. <source>J Pharmacokinet Biopharm</source>. <year>1995</year>;<volume>23</volume>:<fpage>101</fpage>-<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010397731">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dodds</surname><given-names>MG</given-names></name>
<name><surname>Hooker</surname><given-names>AC</given-names></name>
<name><surname>Vicini</surname><given-names>P</given-names></name>
</person-group>. <article-title>Robust population pharmacokinetic experiment design</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2005</year>;<volume>32</volume>:<fpage>33</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010397731">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>AC</given-names></name>
<name><surname>Bogacka</surname><given-names>B</given-names></name>
</person-group>. <article-title>Compound and other optimal designs for systems of nonlinear differential equations arising in chemical kinetics</article-title>. <source>Chemometrics Intelligent Lab Syst</source>. <year>2002</year>;<volume>61</volume>:<fpage>17</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010397731">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Foracchia</surname><given-names>M</given-names></name>
<name><surname>Hooker</surname><given-names>A</given-names></name>
<name><surname>Vicini</surname><given-names>P</given-names></name>
<name><surname>Ruggeri</surname><given-names>A</given-names></name>
</person-group>. <article-title>POPED, a software for optimal experiment design in population kinetics</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2004</year>;<volume>74</volume>:<fpage>29</fpage>-<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010397731">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nyberg</surname><given-names>J</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Hooker</surname><given-names>AC</given-names></name>
</person-group>. <article-title>Simultaneous optimal experimental design on dose and sample times</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2009</year>;<volume>36</volume>:<fpage>125</fpage>-<lpage>145</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010397731">
<label>15.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Jonsson</surname><given-names>EN</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Milligan</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Graphical displays for modeling population data</article-title>. In: <person-group person-group-type="editor">
<name><surname>Ette</surname><given-names>EI</given-names></name>
<name><surname>Williams</surname><given-names>PJ</given-names></name>
</person-group>, eds. <source>Pharmaco-metrics: The Science of Quantitative Pharmacology</source>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley and Sons, Inc, Publications</publisher-name>; <year>2007</year>: <fpage>183</fpage>-<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010397731">
<label>16.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Davidian</surname><given-names>M</given-names></name>
<name><surname>Giltinan</surname><given-names>DM</given-names></name>
</person-group>. <source>Nonlinear Models for Repeated Measurement Data (Monographs on Statistics and Applied Probability 62)</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman and Hall</publisher-name>; <year>1998</year>.</citation>
</ref>
<ref id="bibr17-0091270010397731">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wählby</surname><given-names>U</given-names></name>
<name><surname>Jonsson</surname><given-names>EN</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
</person-group>. <article-title>Assessment of actual significance levels for covariate effects in NONMEM</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2001</year>;<volume>28</volume>:<fpage>231</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010397731">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holford</surname><given-names>NH</given-names></name>
</person-group>. <article-title>A size standard for pharmacokinetics</article-title>. <source>Clin Pharmacokinet</source>. <year>1996</year>;<volume>30</volume>:<fpage>329</fpage>-<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010397731">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>AC</given-names></name>
<name><surname>Bogacka</surname><given-names>B</given-names></name>
</person-group>. <article-title>Compound D- and Ds- optimal designs for determining the order of a chemical reaction</article-title>. <source>Technometrics</source>. <year>1997</year>;<volume>39</volume>:<fpage>347</fpage>-<lpage>356</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>